UPDATE: Barrington Research Reiterates Outperform Rating, Raises PT on NuVaisve on Multiple Positive Factors

In a report published Tuesday, Barrington Research analyst Charley Jones reiterated an Outperform rating on NuVasive

, and raised the price target from $25.00 to $27.00. In the report, Jones noted, “We are reiterating our OUTPERFORM investment rating of NUVA and increasing our price target to $27 from $25 based on the company's technology leadership, increasing revenue per procedure, growing sales bag and strong history of market share gains.Our price target is based on an EV/Revenue multiple of 1.3x our FY/13 revenue estimate of $655 million.” NuVasive closed on Monday at $23.26.